4.6 Article

Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure An Observational Study

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 14, 期 16, 页码 1815-1826

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2021.05.042

关键词

procedural safety; procedure guidance; technical success; transesophageal echocardiography; left atrial appendage closure

资金

  1. Swiss Heart Foundation
  2. Abbott Vascular
  3. Biotronik
  4. Boston Scientific
  5. HeartFlow
  6. Sanofi
  7. Regeneron
  8. Medtronic
  9. Abbott
  10. Amgen
  11. Bristol Myers Squibb
  12. Bayer
  13. Cardinal Health
  14. CSL Behring
  15. Daiichi-Sankyo
  16. Edwards Lifesciences
  17. Johnson Johnson
  18. Querbet
  19. Polares
  20. Sinomed
  21. Terumo
  22. AstraZeneca
  23. Alvimedica/CID
  24. Opsens
  25. CoreFLOW
  26. Idorsia Pharmaceuticals
  27. Universitat Basel Department Klinische Forschung
  28. Vifor
  29. iVascular
  30. Medscape

向作者/读者索取更多资源

This study found that the addition of intraprocedural echocardiography to guide LAAC procedures can reduce the risk of procedural complications and improve technical success rates in the mid-term.
OBJECTIVES The aim of this study was to evaluate the impact of echocardiographic guidance on the safety and efficacy of left atrial appendage closure (LAAC). BACKGROUND Expert consensus documents recommend intraprocedural imaging by means of either transesophageal echocardiography or intracardiac echocardiography to guide LAAC. However, no evidence exists that intraprocedural echocardiographic guidance in addition to fluoroscopy improves the safety and efficacy of LAAC. METHODS Consecutive LAAC procedures performed at a high-volume center between January 2009 and October 2020 were stratified on the basis of intraprocedural imaging modalities, including fluoroscopic guidance (FG) only or intraprocedural echocardiographic guidance (EG) in addition to fluoroscopy. The primary safety endpoint was the composite of procedure-related complications occurring within 7 days after the procedure. Technical success at 7 days and at follow-up were secondary endpoints. RESULTS Among 811 LAAC procedures, 549 (67.7%) and 262 (32.3%) were assigned to the FG and EG groups, respectively. After adjusting for confounders, EG remained associated with a lower rate of the primary safety endpoint (3.4% vs 9.1%; P = 0.004; adjusted odds ratio [OR]: 0.31; 95% CI: 0.11-0.90; P = 0.030). Technical success trended higher at 7 days (92.1% vs 87.2%; P = 0.065; adjusted OR: 1.68; 95% CI: 0.95-3.01; P = 0.079) and was significantly improved with EG compared with FG (87.6% vs 79.9%; P = 0.018; OR: 4.06; 95% CI: 1.60-10.27; P = 0.003) after a median follow-up period of 4.9 months (interquartile range: 3.4 months-6.2 months). CONCLUSIONS In a large cohort of consecutive LAACs, the use of intraprocedural echocardiography to guide intervention in addition to standard fluoroscopy was associated with lower risks for procedural complications and higher mid-term technical success rates. (J Am Coll Cardiol Intv 2021;14:1815-1826) (c) 2021 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据